APT Medical (SHSE:688617) EBIT: ¥1,062 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688617 APT Medical Inc SHSE:688617
78 GF Score
Price ¥239.60
GF Value ¥366.17
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is APT Medical EBIT?

APT Medical SHSE:688617 -1.35% 78 EBIT is ¥1,062 Mil as of Jun. 2026. GuruFocus rates SHSE:688617 with a GF Score™ of 78/100 and a GF Value™ of ¥366.17 (Significantly Undervalued). The stock has 1 warning sign investors should review.

APT Medical's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was ¥338 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1,062 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. APT Medical's annualized ROC % for the quarter that ended in Jun. 2026 was 64.99%. APT Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 123.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. APT Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 3.22%.


APT Medical  (SHSE:688617) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

APT Medical's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=1351.408 * ( 1 - 10.54% )/( (1862.643 + 1857.576)/ 2 )
=1208.9695968/1860.1095
=64.99 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3430.505 - 276.889 - ( 1290.973 - max(0, 361.858 - 1882.479+1290.973))
=1862.643

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3618.452 - 336.73 - ( 1424.146 - max(0, 437.839 - 2045.744+1424.146))
=1857.576

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

APT Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1351.136/( ( (863.305 + max(233.029, 0)) + (893.824 + max(189.349, 0)) )/ 2 )
=1351.136/( ( 1096.334 + 1083.173 )/ 2 )
=1351.136/1089.7535
=123.99 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.73 + 480.364 + 48.814) - (276.889 + 0 + 76.99)
=233.029

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(76.144 + 492.727 + 49.159) - (336.73 + 0 + 91.951)
=189.349

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

APT Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=1061.784/32995.027
=3.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


APT Medical EBIT Related Terms


APT Medical EBIT Historical Data

* Premium members only.

The historical data trend for APT Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

APT Medical EBIT Chart

APT Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 223.18 396.58 600.06 747.97 937.75

APT Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 264.81 226.94 231.02 266.05 337.78

SHSE:688617 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, APT Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


APT Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, APT Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where APT Medical's EV-to-EBIT falls into.


SHSE:688617
78GF Score
APT Medical Inc SHSE:688617
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

APT Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,062 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥1,062 Mil mean?
APT Medical (SHSE:688617) has a EBIT of ¥1,062 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on APT Medical.
Is APT Medical's EBIT too high?
APT Medical's current EBIT is ¥1,062 Mil. Overall, APT Medical has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does APT Medical's EBIT compare to ABT and SYK?
APT Medical's EBIT of ¥1,062 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on APT Medical. APT Medical's current EBIT is ¥1,062 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is APT Medical stock overvalued right now?
Based on GuruFocus' analysis, APT Medical (SHSE:688617) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥366.17, compared to a current price of ¥239.60 — trading 34.6% below its estimated fair value. The current EBIT is ¥1,062 Mil. APT Medical's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For APT Medical (SHSE:688617), the current EBIT is ¥1,062 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is APT Medical (SHSE:688617) Overvalued in 2026?

Based on GuruFocus' analysis, APT Medical stock appears to be undervalued. The current stock price of ¥239.60 is trading 34.6% below its estimated GF Value™ of ¥366.17. GuruFocus considers APT Medical to be Significantly Undervalued.

Key valuation signals for SHSE:688617:

  • EBIT: ¥1,062 Mil
  • GF Value™: ¥366.17 vs. price of ¥239.60 (34.6% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


APT Medical Business Description

Address No. 11, Songpingshan Langshan Road, Xili Street, Room 601, Building B, Tongfang Information Port, Songpingshan Community, Nanshan District, Guangdong Province, Shenzhen, CHN, 518000
APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.
78GF Score

Get the complete analysis for SHSE:688617

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥239.60
Price
¥366.17
GF Value